Log In Sign up
The largest database of trusted experimental protocols

αcd8 2

Manufactured by BioXCell
Visit Supplier

The αCD8 (2.43) is a laboratory product that functions as a monoclonal antibody. It is designed for use in cell biology research applications.

Automatically generated - may contain errors

Lab products found in correlation

αcd4 gk1, by BioXCell (3 mentions) αpd 1 29f 1a12, by BioXCell (2 mentions) αctla 9h10, by BioXCell (2 mentions) αcd40 fgk4, by BioXCell (2 mentions) 1 2 distearoyl sn glycero 3 phosphoethanolamine n maleimide polyethylene glycol 2000, by Avanti Polar Lipids (2 mentions) Rb6 8c5, by BioXCell (1 mentions)

Spelling variants of this product

αCD8 (2.43 clone, (2 citations)

5 protocols using αcd8 2

1

Immunotherapy Regimen for Preclinical Cancer

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All antibody dosing was performed via intraperitoneal injection in PBS. αCD4 (GK1.5, BioXCell) and αCD8 (2.43, BioXCell) depleting antibodies were administered at 200 ug every 4 days. αPD-1 (29F.1A12, BioXCell) was administered at 200 μg three times a week. αCTLA (9H10, BioXCell) was administered at an initial dose of 200 μg, with all subsequent doses at 100 μg, three times a week. αCD40 (FGK4.5, BioXCell) was administered once at the beginning of treatment at 100 μg.
The adjuvant amphiphile-CpG (amph-CpG) and antigen amphiphile (amph-peptide) were produced as previously described53 (link). Briefly, class B CpG 1826 oligonucleotide with a G2 spacer (5’-diacyl lipid-GGTCCATGACGTTCCTGACGTT- 3’) was conjugated via the 5’ end to an 18 carbon diacyl tail. Antigen peptide OVA250–270 (CGLEQLESIINFEKLTEWTSS) and non-specific mutant gp10020–39 (optimized S27P, EGP long52 (link), CAVGALEGPRNQDWLGVPRQL) were conjugated via N’ cysteine residue to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol-2000] (Avanti Polar Lipids). Mice were vaccinated subcutaneously at the base of the tail with 1.24 nmol amph-CpG and 25 μg of amph-peptide, with half dose given to each side. Vaccination was performed once weekly starting 14 days post-transplant of loSIIN organoids.
Westcott P.M., Sacks N.J., Schenkel J.M., Ely Z.A., Smith O., Hauck H., Jaeger A.M., Zhang D., Backlund C.M., Beytagh M.C., Patten J., Elbashir R., Eng G., Irvine D.J., Yilmaz O.H, & Jacks T. (2021). Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature cancer, 2(10), 1071-1085.
+ Open protocol
+ Expand
2

Monoclonal Antibodies for T Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following monoclonal antibodies (mAb) for flow cytometry, with or without a fluorescent conjugate, were obtained from Biolegend (San Diego, CA): αCD4 (GK 1.5 and RM4-5), αCD8 (53-6.7), αT-bet (4B10), αCD62L (MEL-14), αFoxP3 (FJK-16s), αIFN-γ (XMG1.2), αTNFα (TN3-19.12), Rictor (H-11) αCD4 (GK1.5) and αCD8 (2.43) antibodies for T cell depletion were purchased from BioXcell (West Lebanon, NH). Ezetimibe was purchased from Par Phamaceutical (Chestnut Ridge,NY). Antibodies for Western blotting against the following targets were purchased from Cell Signaling Technology (Danvers, MA): p-p70S6K (T389), p70S6K (49D7), pAKT (S473), pAKT (T308), AKT(C67E7), P-4E-BP1 (T37/46), 4E-BP1 (53H1), CPTA (5D8G9), pSGK (D36D11), SGK (D27C11), pPKCα (Thr638), PKCα (Polyclonal ab), pPKCζ (T410/403), PKCζ (D10E2). Antibody against β-actin (AC-15) was purchased from Sigma (Ronkonkoma, NY).
Wang Y., You S., Su S., Yeon A., Lo E.M., Kim S., Mohler J.L., Freeman M.R, & Kim H.L. (2021). Cholesterol-lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(2), 414-424.
+ Open protocol
+ Expand
3

Immunomodulation in Orthotopic Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
To deplete CD4+ or CD8+ T cells, Batf3–/– mice bearing CB+ orthotopic tumors were treated with 200 μg of αCD4 (GK1.5, BioXcell) i.p. on days –1, 1, 4, and/or 200 μg of αCD8 (2.43, BioXcell) i.p. on days –1, 5, and 10. A total of 400 μg of αCD20 (SA271G2, BioLegend) on day –1 relative to tumor implantation was used to deplete B cells. A total of 400 μg of αCSF1R (AFS98, BioXcell), 200 μg of αGr-1 (RB6-8C5, BioXcell), or 200–250 μL of control liposomes or clodronate-loaded liposomes (Encapsula NanoSciences) were administered i.p. on days –1, 1, 3, 5, 7, 9, and 11 relative to orthotopic tumor implantation.
Burrack A.L., Schmiechen Z.C., Patterson M.T., Miller E.A., Spartz E.J., Rollins M.R., Raynor J.F., Mitchell J.S., Kaisho T., Fife B.T, & Stromnes I.M. (2022). Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. JCI Insight, 7(7), e151593.
+ Open protocol
+ Expand
4

CD4+ and CD8+ Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols
For immunogenicity studies, mice were depleted of CD4+ or CD8+ cells in the priming phase by once daily intraperitoneal doses of 200 µg αCD4 (GK1.5, Bio X Cell) or αCD8 (2.43, Bio X Cell), respectively, for three consecutive days prior to vaccine/αhCD27 administration (as previously described), and immune responses were assessed at day 7 after vaccination. For survival studies, CD8+ cells were depleted by once daily intraperitoneal administration of 200 µg αCD8 for three consecutive days immediately after intracranial tumor implantation and before Ova/αhCD27 treatment. For CD4 depletion studies in tumor-bearing mice, a tumor challenge model was employed in which mice were implanted with intracranial B16.OVA tumors seven days after vaccination with whole Ova protein and αhCD27; CD4+ cells were depleted by once daily intraperitoneal administration of 200 µg αCD4 for three consecutive days prior to Ova/αhCD27 vaccination (priming phase) or for three consecutive days immediately after intracranial tumor implantation (effector phase).
Riccione K.A., He L.Z., Fecci P.E., Norberg P.K., Suryadevara C.M., Swartz A., Healy P., Reap E., Keler T., Li Q.J., Congdon K.L., Sanchez-Perez L, & Sampson J.H. (2018). CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. Oncoimmunology, 7(12), e1502904.
+ Open protocol
+ Expand
5

Immunotherapy Regimen for Preclinical Cancer

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All antibody dosing was performed via intraperitoneal injection in PBS. αCD4 (GK1.5, BioXCell) and αCD8 (2.43, BioXCell) depleting antibodies were administered at 200 ug every 4 days. αPD-1 (29F.1A12, BioXCell) was administered at 200 μg three times a week. αCTLA (9H10, BioXCell) was administered at an initial dose of 200 μg, with all subsequent doses at 100 μg, three times a week. αCD40 (FGK4.5, BioXCell) was administered once at the beginning of treatment at 100 μg.
The adjuvant amphiphile-CpG (amph-CpG) and antigen amphiphile (amph-peptide) were produced as previously described53 (link). Briefly, class B CpG 1826 oligonucleotide with a G2 spacer (5’-diacyl lipid-GGTCCATGACGTTCCTGACGTT- 3’) was conjugated via the 5’ end to an 18 carbon diacyl tail. Antigen peptide OVA250–270 (CGLEQLESIINFEKLTEWTSS) and non-specific mutant gp10020–39 (optimized S27P, EGP long52 (link), CAVGALEGPRNQDWLGVPRQL) were conjugated via N’ cysteine residue to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol-2000] (Avanti Polar Lipids). Mice were vaccinated subcutaneously at the base of the tail with 1.24 nmol amph-CpG and 25 μg of amph-peptide, with half dose given to each side. Vaccination was performed once weekly starting 14 days post-transplant of loSIIN organoids.
Westcott P.M., Sacks N.J., Schenkel J.M., Ely Z.A., Smith O., Hauck H., Jaeger A.M., Zhang D., Backlund C.M., Beytagh M.C., Patten J., Elbashir R., Eng G., Irvine D.J., Yilmaz O.H, & Jacks T. (2021). Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature cancer, 2(10), 1071-1085.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!